Oryzon Genomics S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Carlos Manuel Buesa Arjol
- Full Time Employees
- 47
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Sant Ferran 74 Cornellà de Llobregat Spain 08940
- IPO Date
- Dec 15, 2020
- Website
- oryzon.com
- Similar Companies
- Business
- Oryzon Genomics S.A. Oryzon Genomics S.A. (ORYZF), a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Cornellà de Llobregat, Spain, leads Europe in epigenetics-based therapeutics targeting lysine specific demethylase 1 (LSD1) for oncology, central nervous system (CNS) disorders, psychiatric diseases, and non-oncological hematological conditions; its core pipeline includes iadademstat (ORY-1001), a potent selective LSD1 inhibitor in Phase II trials for acute myeloid leukemia, small cell lung cancer, and sickle cell disease via the RESTORE Phase Ib trial, vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor in multiple Phase II trials for CNS and psychiatric disorders with Phase III readiness, ORY-3001 an LSD1 inhibitor in preclinical development for non-oncological diseases, and ORY-4001 a selective HDAC6 inhibitor nominated for clinical development in Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis; the company maintains operations in Spain, the United States, and supports personalized medicine through biomarker platforms. In 2025, Oryzon Genomics secures €52 million ($61 million) in financing including a €30 million capital increase issuing 12.8 million new shares at €2.35 apiece, €7 million in bank loans, a €13.2 million EU grant, and €1.8 million in R&D incentives to bolster its balance sheet, advance clinical programs, and prepare for potential Nasdaq dual listing and partnerships; it receives positive FDA feedback on a revised Phase III protocol for vafidemstat in borderline personality disorder, strengthening its CNS-focused strategy with enhanced regulatory and clinical teams; additionally, the company terminates a convertible bonds facility with Nice & Green, expands iadademstat via a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute for hematologic and solid cancers, and reports improved net results for Q3 2025 while presenting positive clinical data at ASH 2025.
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
ORYZON to Participate in Upcoming Events in November
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
ORYZON to Host Virtual KOL Event on July 9, 2025
ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
ORYZON to Provide Corporate Progress Updates at Several Events in March-April
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting